Modulation of the atopy patch test: tacrolimus 0.1% compared with triamcinolone acetonide 0.1%

Area of Science:

• Dermatology
• Immunology
• Allergology

Background:

• The atopy patch test (APT) is an established in vivo model for studying eczema induction by inhalant allergens in atopic dermatitis (AD) patients.
• Investigating the efficacy of topical treatments on skin responses to allergens is crucial for managing AD.

Purpose of the Study:

• To evaluate the effect of pretreatment with topical tacrolimus 0.1% on the APT in nonlesional skin of AD patients.
• To compare tacrolimus's effect with a placebo and a positive control (triamcinolone acetonide).

Main Methods:

• Eight AD patients underwent daily pretreatment with tacrolimus 0.1% ointment, cetomacrogol ointment (placebo), or triamcinolone acetonide 0.1% ointment on nonlesional back skin for 3 weeks.
• The APT was performed, and skin samples were collected at 0 and 24 hours post-application for immunohistochemical analysis.

Main Results:

• Tacrolimus 0.1% ointment did not suppress skin infiltrate or macroscopically inhibit the APT, unlike triamcinolone acetonide.
• Tacrolimus showed no significant difference from placebo in the influx of T cells, eosinophils, dendritic cells, CD64+, and Fc epsilon RI-positive cells.
• Only CD36+ and CD68-positive cells were inhibited by tacrolimus compared to placebo, while triamcinolone acetonide significantly inhibited all tested cell types.

Conclusions:

• Pretreatment with topical tacrolimus 0.1% ointment does not inhibit the atopy patch test reaction in patients with atopic dermatitis.
• These findings suggest tacrolimus may not be effective in preventing allergen-induced eczema in nonlesional skin of AD patients via the APT model.